Quick Answer
ACTUATE THERAPEUTICS, INC. reported Operating Income Loss of -$22.50 million for the year ending 2025.
- ACTUATE THERAPEUTICS, INC. showed an increase of +10.6% in Operating Income Loss from 2024 to 2025.
- This data is from ACTUATE THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2023: -$5.58 million | Q3 2023: -$6.48 million | Q1 2024: -$7.77 million | Q2 2024: -$5.44 million | Q3 2024: -$5.39 million | Q1 2025: -$6.37 million | Q2 2025: -$5.97 million | Q3 2025: -$5.47 million.
- Over the full 3 years of available data (2023 to 2025), ACTUATE THERAPEUTICS, INC.'s Operating Income Loss has grown by 9.9%.
- Historical annual values: Fiscal year 2025: -$22.50 million | Fiscal year 2024: -$25.16 million | Fiscal year 2023: -$24.97 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: